April 15, 2008 – Swedish-based NOLabs AB today said it has achieved an important milestone in the development of a new preventive therapy against urinary tract infection (UTI) using nitric oxide-containing medical devices.
In experiments performed at the Karolinska University Hospital in Sweden, researchers showed that technology developed by NOLabs AB proved to have a high effectiveness in killing pathogens, typically for those causing UTI including an aggressive strain of E. coli. Millions of patients annually acquire UTI while being hospitalized for treatment of other diseases. Preventing such infection has the potential to dramatically reduce the amount of antibiotics used as well as improving quality of life for a large number of hospitalized patients.
The company hopes to have its first products using the technology on the market in early 2009.
“This new technology has a huge potential to reduce the usage of antibiotics and thereby the risk of antibiotic resistance as well as reducing the risk of urosepsis, the severest and potentially lethal consequence of UTI,” said professor Peter Wiklund of Karolinska University.
NOLabs is developing products that will prevent catheter related urinary tract infections, products that will be effective on reducing neuropathic pain and wound care products with an anti-bacterial effect.
For more information: www.nolabs.com